Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 999 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemolysis Clear all
Completed Phase 2 Interventional

Home Based Massage and Relaxation for Sickle Cell Pain

NCT00066079
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
massage, relaxation
Procedure · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
15 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Oct 24, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

NCT05099874
View directory record Official record
Conditions
Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Interventions
EndeavorRx
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

NCT00009581
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Acetylcholine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

NCT03226678
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Whittier, California • Miami Lakes, Florida • Orange City, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

NCT00445978
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Sapropterin Dihydrochloride
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Savannah, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Not applicable Interventional Results available

Music Therapy in Sickle Cell Transition Study

NCT02466555
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 23 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 24, 2026, 2:25 AM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Not applicable Interventional Results available

Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial

NCT03462511
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
HABIT Intervention, Standard of Care, Education materials
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Manhasset, New York • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

NCT00061750
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 24, 2026, 2:25 AM EDT
Terminated Phase 1Phase 2 Interventional

TRF-1101 Assessment in Sickle Cell Disease

NCT00773890
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TRF-1101, Placebo
Drug
Lead sponsor
TRF Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced Oct 24, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Neuroimaging of Pain Using EEG and fMRI

NCT02212691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Not applicable Interventional

The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT

NCT02729350
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Guided Relaxation video clip, Sickle Cell Disease Experience Discussion
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

NCT01702246
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Simvastatin
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 24, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional

Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

NCT03353584
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Virtual Reality Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
alpha-lipoic acid and acetyl-L-carnitine, Control
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 2:25 AM EDT
Terminated Not applicable Interventional

Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease

NCT03577691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Training for use of web based Decision Aid, No training for use of web based Decision Aid, Pretest surveys and posttest surveys, Only posttest surveys
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 2:25 AM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 24, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease

NCT01123369
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04691570
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901
View directory record Official record
Conditions
Sickle Cell Disease, Priapism
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises

NCT00094887
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 24, 2026, 2:25 AM EDT
Completed No phase listed Observational

Heart Disease in Sickle Cell Anemia

NCT00113152
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 2:25 AM EDT